We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Two-year follow-up of docosahexaenoic acid supplementation in spinocerebellar ataxia type 38 (SCA38).
- Authors
Gazulla, José; Benavente, Isabel; García-González, Elena; Berciano, José
- Abstract
Analysis of SARA item scores revealed statistically significant reductions in the stance and heel-shin slide scores, and in total SARA scores, after 78- and 104-week DHA supplementation with respect to baseline, similar results to those at 13 and 26 weeks [[5]]. To the Editor: Spinocerebellar ataxia type 38 is an infrequent autosomal dominant disease caused by mutations in I ELOVL5 i , which encodes for the ELOVL5 enzyme. The DHA group experienced a clinical improvement and a statistically significant reduction in total SARA scores, compared to the placebo group; however, the characteristics of the clinical amelioration were not detailed, and scores of individual SARA items were not provided.
- Subjects
SPINOCEREBELLAR ataxia; CEREBELLUM degeneration; DOCOSAHEXAENOIC acid; DIETARY supplements
- Publication
Journal of Neurology, 2022, Vol 269, Issue 10, p5643
- ISSN
0340-5354
- Publication type
Article
- DOI
10.1007/s00415-022-11138-3